Tri Chemical Laboratories Inc. (TYO:4369)
3,065.00
+101.00 (3.41%)
Sep 4, 2026, 3:30 PM JST
Tri Chemical Laboratories Revenue
Tri Chemical Laboratories had revenue of 7.22B JPY in the quarter ending July 31, 2026, with 24.33% growth. This brings the company's revenue in the last twelve months to 26.21B, up 12.48% year-over-year. In the fiscal year ending January 31, 2026, Tri Chemical Laboratories had annual revenue of 23.88B with 26.33% growth.
Revenue (ttm)
26.21B
Revenue Growth
+12.48%
P/S Ratio
3.80
Revenue / Employee
83.75M
Employees
313
Market Cap
99.60B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 31, 2026 | 23.88B | 4.98B | 26.33% |
| Jan 31, 2025 | 18.91B | 7.66B | 68.10% |
| Jan 31, 2024 | 11.25B | -2.56B | -18.52% |
| Jan 31, 2023 | 13.80B | 2.23B | 19.26% |
| Jan 31, 2022 | 11.57B | 1.77B | 18.09% |
| Jan 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chori | 303.57B |
| Sumitomo Seika Chemicals Company, Limited. | 153.18B |
| Central Glass | 148.87B |
| Konishi | 140.53B |
| Dainichiseika Color & Chemicals Mfg. | 127.17B |
| Unitika | 111.76B |
| Okamoto Industries | 110.03B |
| Osaka Organic Chemical Industry | 38.90B |
Tri Chemical Laboratories News
- 5 days ago - Tri Chemical Laboratories Quarterly report: Q2 2027 - Filings
- 3 months ago - Tri Chemical Laboratories Quarterly report: Q1 2027 - Filings
- 5 months ago - Tri Chemical Laboratories Quarterly report: Q4 2026 - Filings
- 9 months ago - Tri Chemical Laboratories Quarterly report: Q3 2026 - Filings